Trial Profile
A Single−Dose, Fixed-Sequence, Two-Period Study to Evaluate the Absorption, Distribution, Metabolism, Excretion of TD-4208 Following an IV Infusion and an Oral Dose of [14C]−Labeled TD−4208 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2021
Price :
$35
*
At a glance
- Drugs Revefenacin (Primary) ; Revefenacin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Mylan Pharmaceuticals Inc.
- 25 Sep 2020 Results published in the Drug Metabolism and Disposition
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 18 May 2016 New trial record